Submitted To:- C.P.

Thakor Sir

Submitted By :- 1) Bhola Aabidali Asagarali

2) Mehta Aaisha Rajnikant
3) Makhija Vaibhav Manharbhai
4) Patel Vaibhavi Vinodbhai :- ABSENT
Introduction:-

 India is the largest provider of generic drugs globally.

Indian pharmaceutical sector industry supplies over 50 per
cent of global demand for various vaccines, 40 per cent of
generic demand in the US and 25 per cent of all medicine
in UK.
 India enjoys an important position in the global
pharmaceuticals sector. The country also has a large pool of
scientists and engineers who have the potential to steer the
industry ahead to an even higher level. Presently over 80
per cent of the antiretroviral drugs used globally to combat
AIDS (Acquired Immune Deficiency Syndrome) are
supplied by Indian pharmaceutical firms.
Growth Of Industry:-

 The Union Cabinet has given its nod for the amendment of the
existing Foreign Direct Investment (FDI) policy in the
pharmaceutical sector in order to allow FDI up to 100 per cent
under the automatic route for manufacturing of medical devices
subject to certain conditions.
 The drugs and pharmaceuticals sector attracted cumulative FDI
inflows worth US$ 15.98 billion between April 2000 and March
2019, according to data released by the Department of Industrial
Policy and Promotion (DIPP).
Market Overview Of Pharmaceutical
Industry:-
 The pharmaceutical sector was valued at US$ 33 billion in 2017. The
country’s pharmaceutical industry is expected to expand at a CAGR of 22.4
per cent over 2015–20 to reach US$ 55 billion. India’s pharmaceutical
exports stood at US$ 17.27 billion in FY18 and have reached US$ 19.14
billion in FY19. Pharmaceutical exports include bulk drugs, intermediates,
drug formulations, biologicals, Ayush & herbal products and surgical.

 Indian companies received 304 Abbreviated New Drug Application

(ANDA) approvals from the US Food and Drug Administration (USFDA)
in 2017. The country accounts for around 30 per cent (by volume) and about
10 per cent (value) in the US$ 70-80 billion US generics market.

 India's biotechnology industry comprising bio-pharmaceuticals, bio-

services, bio-agriculture, bio-industry and bioinformatics is expected grow
at an average growth rate of around 30 per cent a year and reach US$ 100
billion by 2025.
International Scenario:-
 Pharmaceutical industries viz., Ranbaxy, cipla, nicolos, zydus,
intas etc. Are very well establish
 Now-a-days and producing A large variety of medicine useful
in the treatment of various diseases.
 It is now high-end development that is being carried out by
leading companies whereas other
 Small companies are finding themselves competing against, or
working with, new innovation based companies to establish
themselves in the market in concern to increase their
productivity
 And finally sale. The present study was focuses on the current
scenario of various pharmaceutical Industry.
Major Players Of Pharmaceutical
Industry:-

 Sun Pharmaceuticals is the largest pharmaceutical company

from India and the fifth largest specialty generic company in
the world. It has capabilities across dosage forms like
injectables, sprays, ointments, creams, liquids, tablets and
capsules. Its businesses include producing generics, branded
generics, speciality, over the counter (OTC) products, anti-
retrovirals (ARVs), Active Pharmaceutical Ingredients (APIs)
and intermediates in the full range of dosage forms. It also
produces specialty APIs. US formulations contributed the most
to company’s US$ 4 billion sales in FY18 with a contribution
of 34 per cent, followed by India branded formulations at 31
per cent.
 Cipla is a leading pharmaceutical from India with presence
across the world. It was established in 1935 as Chemical
Industrial & Pharmaceutical Laboratories Ltd and changed to
its current name in 1984. The company has a vast portfolio
with more than 1,500 products in the market. The company’s
business is divided into three strategic units - Active
Pharmaceutical Ingredients (API), Respiratory and Cipla
Global Access. Its largest market is India which contributed 39
per cent to its revenues in FY18, followed by Africa and North
America with contribution of 22 per cent and 17 per cent,
respectively. In FY19, total revenue of the company reached Rs
16,362 crore (US$ 2.36 billion).
 Lupin Ltd is a leading pharmaceutical company from India and
is amongst the top 10 generic companies in the world. It started
its business in 1968 and over the years has become one of the
largest pharmaceutical companies in India and the world. Its
businesses include formulations, Active Pharmaceutical
Ingredients (API), drug delivery systems and biotechnology. Its
largest market is the North American region which contributed
38 per cent of its revenues in FY18, followed by India with 26
per cent and Asia-Pacific (APAC) with 17 per cent. In FY19,
its total sales reached Rs 16,369.4 crore (US$ 2.34 billion) and
in H1FY20 reached Rs 8,652.7 crore (US$ 1.24 billion).
Impact on Business:-

 The Indian pharma industry covers the global share of around

1–2% share. It has been growing at a rapid speed of
approximately 10% every year.
 The Pharmaceuticals industry was an estimated USD 7 billion
in 2016 which is growing at a rate of CAGR 15.92 percent.
 Conclusion:-

 Our country has been mainly involved in the Process patents

(& not product patents) which makes manufacturing the
biggest benefit. The results were a glorifying history. With
rising living standards, the credibility is shifting to more
creativity to attain more of patent drugs in coming times. Our
country is ranked thirteen in terms of size which is said to beat
it to a better position sooner.